ReviewNature reviews. Drug discovery2011
The influence of the 'organizational factor' on compound quality in drug discovery.
Review in Nature reviews. Drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Solvent-Site Prediction for Fragment Docking and Its Implication on Fragment-Based Drug Discovery.Journal of chemical information and modeling · 2025Article
- How strong the interaction really are? Application of nanoITC in the analysis of the interaction between newly synthesized substances with potential anticancer activity and model carrier proteins.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- A least-squares-fitting procedure for an efficient preclinical ranking of passive transport across the blood-brain barrier endothelium.Journal of computer-aided molecular design · 2023Article
- Systematic Modification of the Substitution Pattern of the 7-Hydroxy-5-oxopyrazolo[4,3-Molecules (Basel, Switzerland) · 2023Article
- Lipophilicity Modulations by Fluorination Correlate with Membrane Partitioning.Angewandte Chemie (International ed. in English) · 2023Article
- TheACS medicinal chemistry letters · 2022Article
- Article
- Dynamics of cumulative advantage and threats to equity in open science: a scoping review.Royal Society open science · 2022Article
- Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies.Journal of medicinal chemistry · 2021Article
- Synthesis of Degraded Limonoid Analogs as New Antibacterial Scaffolds againstAntibiotics (Basel, Switzerland) · 2020Article
- Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine.The Journal of pharmacology and experimental therapeutics · 2020Article
- Utility of Physicochemical Properties for the Prediction of Toxicological Outcomes: Takeda Perspective.ACS medicinal chemistry letters · 2020Article
- Setting Our Sights on Infectious Diseases.ACS infectious diseases · 2020Article
- Beware of ligand efficiency (LE): understanding LE data in modeling structure-activity and structure-economy relationships.Journal of cheminformatics · 2017Article
- The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.Pharmaceutical research · 2017Review
- Lipophilicity in Drug Development: Too Much or Not Enough?The AAPS journal · 2016Article
- Twenty years on: the impact of fragments on drug discovery.Nature reviews. Drug discovery · 2016Review
- Applications of (19)F-NMR in Fragment-Based Drug Discovery.Molecules (Basel, Switzerland) · 2016Review
- Prioritization of anti-malarial hits from nature: chemo-informatic profiling of natural products with in vitro antiplasmodial activities and currently registered anti-malarial drugs.Malaria journal · 2016Article
- Molecular Property Design: Does Everyone Get It?ACS medicinal chemistry letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Physicochemical properties such as lipophilicity and molecular mass are known to have an important influence on the absorption, distribution, metabolism, excretion and toxicity (ADMET) profile of small-molecule drug candidates. To assess the use of this knowledge in reducing the likelihood of compound-related attrition, the molecular properties of compounds acting at specific drug targets described in patents from leading pharmaceutical companies during the 2000-2010 period were analysed. Over the past decade, there has been little overall change in properties that influence ADMET outcomes, but there are marked differences in molecular properties between organizations, which are maintained when the targets pursued are taken into account. The target-unbiased molecular property differences, which are attributable to divergent corporate drug design strategies, are comparable to the differences between the major drug target classes. On the basis of our analysis, we conclude that a substantial sector of the pharmaceutical industry has not modified its drug design practices and is still producing compounds with suboptimal physicochemical profiles.
Indexed as
Identifiers
21959288What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.